Growth Hormone Deficiency (GHD)
Endocrinology
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Opko HealthMOD-4023
Ascendis PharmaACP-001
Clinical Trials (2)
Total enrollment: 53 patients across 2 trials
Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
Start: Feb 2014Est. completion: Nov 2023
Phase 2Completed
Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
Start: Jul 2013Est. completion: Sep 201553 patients
Phase 2Completed
Related Jobs in Endocrinology
Research Associate I/II - Biology
Marea Therapeutics
South San Francisco
1w ago
$90K - $120K/yr
Associate Director, Clinical Operations
Marea Therapeutics
South San Francisco
3w ago
$190K - $210K/yr
Associate Director/Director, Regulatory Affairs
Marea Therapeutics
South San Francisco
1mo ago
$185K - $240K/yr
Medical Science Liaison (rare diseases)
Amgen
Poland - Lódz
1mo ago
Senior/Executive Director, Analytical Development
Marea Therapeutics
South San Francisco
1mo ago
$250K - $295K/yr
Senior Clinical Scientist - Job ID: 1845
Ascendis Pharma
Palo Alto, California (Hybrid)
2mo ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space